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http://dx.doi.org/10.1016/j.ccr.2013.08.013SUMMARYRibosomes are specialized entities that participate in regulation of gene expression through their rRNAs
carrying ribozyme activity. Ribosome biogenesis is overactivated in p53-inactivated cancer cells, although
involvement of p53 on ribosome quality is unknown. Here, we show that p53 represses expression of the
rRNA methyl-transferase fibrillarin (FBL) by binding directly to FBL. High levels of FBL are accompanied
by modifications of the rRNA methylation pattern, impairment of translational fidelity, and an increase of
internal ribosome entry site (IRES)-dependent translation initiation of key cancer genes. FBL overexpression
contributes to tumorigenesis and is associated with poor survival in patients with breast cancer. Thus, p53
acts as a safeguard of protein synthesis by regulating FBL and the subsequent quality and intrinsic activity
of ribosomes.INTRODUCTION
Recent findings support the emerging notion that the dysregula-
tion of ribosome biogenesis in cancer cells is not just a conse-
quence of oncogenesis, but represents a key step in this
complex process (Barna et al., 2008; Bywater et al., 2012;
Yoon et al., 2006). Ribosome biogenesis is a multistage process
that involves transcriptional and posttranscriptional regulation
and a stringent quality control to produce functional ribosomesSignificance
Ribosome production is increased in cancer cells. This enhanc
gression. Our results show that p53 regulates the pattern of r
translational fidelity and increases the initiation of internal rib
strating that p53 regulates the biogenesis and intrinsic activity
participates in the ‘‘translational reprogramming’’ in cancer c
oncogenic genes.
318 Cancer Cell 24, 318–330, September 9, 2013 ª2013 Elsevier Inc(Bashan and Yonath, 2008; Henras et al., 2008). Ribosome
biogenesis is overactivated in cancer cells, notably by a loss of
function of RNA polymerase I (Pol I) repressors such as p53
(Bywater et al., 2012; Zhai and Comai, 2000).
The posttranscriptional steps of ribosomal RNA (rRNA) pro-
cessing determine the structure and function of thematuremole-
cule (King et al., 2003; Baxter-Roshek et al., 2007; Puglisi, 2009).
Indeed, rRNAs are ribozymes that support the decoding and
proofreading steps and catalyze the formation of the peptideed production of ribosomes plays a crucial role in tumor pro-
ibosomal RNA posttranscriptional modification that impairs
osome entry site (IRES)-dependent translation. By demon-
of ribosomes, our study demonstrates that p53 deficiency
ells and contributes to the uncontrolled expression of key
.
Figure 1. p53 Regulates FBL Expression at both the mRNA and
Protein Levels
The expression of endogenous FBL in the indicated cell lines was analyzed at
the mRNA level by RT-qPCR (A, C, and E) and at the protein level by western
blot (B, D, and F). All graphs represent mean and SD of at least three experi-
ments. *p < 0.05 and **p < 0.01 according to Student’s t test.
See also Figure S1.
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p53 Regulates Translation by Modulating Fibrillarinbond during translation (Cech, 2000; Demeshkina et al., 2012).
rRNAs are subjected to intense and highly specific chemical
modifications (methylations and pseudouridylations). The exact
role of these modifications has not yet been fully elucidated,
although it appears that they help optimize the complex ribo-
somal architecture required to produce an efficient ribosome
(Baxter-Roshek et al., 2007).
Changes in the posttranscriptional modifications of rRNAs
influence translational fidelity (i.e., nonsense suppression or
amino acid misincorporation) and the mode of translation initia-
tion (i.e., CAP versus internal ribosome entry site [IRES]) of key
cancer genes (Ruggero, 2013; Basu et al., 2011; Baxter-Roshek
et al., 2007). Moreover, a defect in rRNA methylation or pseu-
douridylation may cause specific clinical syndromes and is
correlated with an increased incidence of cancer (Belin et al.,
2009; Montanaro et al., 2008). This study aims to determine
whether p53 controls rRNA methylation and subsequently
affects translational regulation.
RESULTS
FBLExpression Is Inversely Associatedwith p53 Activity
in Cell Lines and Human Breast Cancer Samples
Fibrillarin (FBL) is an indispensable, highly conserved protein
essential in the processing of pre-rRNAs (Newton et al., 2003;
Tollervey et al., 1993). In eukaryotes, it is the only known methyl-
transferase that performs the specific 20-O-ribose-methylation
directed by a large family of small trans-acting guide RNA (box
C/D antisense snoRNAs). Because abnormal rRNA methylation
could influence translational control and because p53 regulates
rRNA transcription, we explored whether FBL expression was
associated with p53 activity. We measured FBLmRNA and pro-
tein levels in different cell lines in which p53 expression and/or
activity was modulated by different strategies. In immortalized
human mammary epithelial cells (HME), p53 activity was
impaired either by reducing its expression using an shRNA
approach (HME-shp53) or by inactivation using an SV40 T/t
antigen trapping strategy (HMLE; Elenbaas et al., 2001). In
response to p53 knockdown or inactivation, there was a signifi-
cant increase in FBL expression: 1.5-fold for the mRNA and
2-fold for the protein (Figures 1A–1D; Figures S1A and S1B avail-
able online). As expected, we observed a decrease in the
expression of CDKN1A, which encodes p21, and MDM2, two
p53 target genes, which validated the reduction in p53 activity
in these cellular models (Figures 1B, 1D, S1A, and S1B). The
inverse correlation between FBL and p53 expression was
confirmed in a second series of immortalized HMEC lines
(Figures S1C and S1D) and in an isogenic human HCT-116 colo-
rectal cellular model: HCT-116-p53+/+ cells that express wild-
type p53 protein and HCT-116-p53/ cells that lack p53 protein
expression (Bunz et al., 1998). FBL mRNA and protein levels
were increased in HCT-116-p53/ cells compared to those of
HCT-116-p53+/+ cells (Figures 1E, 1F, and S1E), demonstrating
that the increase in expression of FBL in response to p53 inacti-
vation is not restricted to mammary cell lines.
To assess more directly the impact of p53 on FBL expression,
HME cells were treated with a p53-specific siRNA instead of an
shRNA to induce a transient knockdown of p53 expression (Fig-
ures 2A, 2B, S2A, and S2B). In this condition, increased FBLCaexpression at the mRNA and protein levels correlated with the
inhibition of p53 expression (Figures 2A and 2B). Taken together,
these results exclude the possibility that the changes in FBL
expression levels resulted from an off-target effect and firmly
link FBL expression to p53 expression. Additionally, to investi-
gate the impact of p53 activation on FBL expression, we treated
HME cells with the topoisomerase inhibitors doxorubicin and
camptothecin, which are prominent activators of p53. The re-
sults showed that the expected p53 induction in response to
treatment was accompanied by a decrease in FBL mRNA and
protein levels (Figures 2C and 2D). Quantification of the western
blots demonstrated a significant association between the in-
crease of p53 protein levels and the decrease of FBL protein
levels (Figures S2C–S2E).ncer Cell 24, 318–330, September 9, 2013 ª2013 Elsevier Inc. 319
Figure 2. Modulation of p53 Expression
Alters FBL Expression
Endogenous FBL expression was analyzed in
HME cells at the mRNA level by RT-qPCR (A and
C) and at the protein level by western blot (B and
D). The p53 expression is modulated by using an
siRNA (A and B) or by treating or not (NT) with
2 mg/ml doxorubicin or 1 nM camptothecin (C and
D). The p21 lanes in (D) were spliced together
from discontinuous lanes of the same blot as
indicated by dotted lines. All graphs represent
mean and SD of at least three experiments. *p <
0.05 and ***p < 0.001 according to Student’s t test.
See also Figure S2.
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frequently inactivated, mainly by mutations (Olivier et al., 2006).
To determine whether FBL expression is associated with p53
mutation status independently of other genetic variations in cell
lines, we analyzed the FBL expression levels in a panel of three
wild-type p53 breast cell lines and fivemutant p53 breast cancer
cell lines. High levels of FBLmRNA and protein were significantly
associated with the expression of mutant p53 (Figures 3A, 3B,
and S3). This result prompted us to investigate the clinical corre-
lation between the p53 mutation status and FBL expression. We
analyzed the FBL mRNA expression levels by RT-qPCR in rela-
tion to the p53 mutation status in a cohort of 80 randomly
selected primary breast tumors (Table S1). Consistent with the
results obtained in cell lines, FBLmRNA levels were significantly
higher in mutant p53 tumors compared to wild-type p53 tumors
(Figure 3C). We also performed a retrospective statistical anal-
ysis of the gene expression array data described by Miller and
colleagues (Miller et al., 2005). FBL mRNA levels were signifi-
cantly higher in mutant p53 tumors (n = 58) than in wild-type
p53 tumors (n = 193; p < 104, t test). Altogether, these results
show a significant and reproducible inverse association between
the p53 level and/or activity and the expression of FBL at both
the mRNA and protein levels, suggesting that p53 can repress
FBL expression in cellular models of breast and colon cancer
as well as in human breast tumors.
p53 Represses FBL Expression by Directly Binding
to DNA
Using the MatInspector software and the p53FamTag database,
two putative p53 responsive elements (p53RE-1 and p53RE-2)
were identified within the FBL intron 1, suggesting a direct tran-
scriptional regulation of FBL expression by p53 (Cartharius et al.,
2005; Sbisa` et al., 2007; Figures 4A and S4A). Based on these
predictions, we developed a luciferase reporter (pFBL-Luc)
assay to assess whether p53 regulates FBL promoter activity.
HCT-116-p53/ cells were cotransfected with pFBL-Luc and
a plasmid expressing either wild-type or mutant p53 protein at320 Cancer Cell 24, 318–330, September 9, 2013 ª2013 Elsevier Inc.detectable protein levels (Figures 4B
and S4B). The coexpression of wild-type
p53 significantly decreased the luciferase
activity by 80%, while no significant vari-
ation in luciferase activity was observed
after co-expression of any p53 mutant.
Similar results were observed in HME-shp53, the coexpression of wild-type, but not mutant, p53 pro-
tein reducing the luciferase activity (Figure 4C). These results
suggest that p53 represses promoter activity through intron 1
of FBL in both breast and colon cellular models.
To determine whether p53 directly binds to FBL gene DNA,
chromatin immunoprecipitation (ChIP) assays were performed
in HME-derived cells (Figures 4D, 4E, S4C, and S4D). Compared
to nontreated HME cells, camptothecin treatment increased
p53 binding to both the CDKN1A promoter and the intron 1 of
FBL at p53RE-1 and p53RE-2. In contrast, decrease in p53
expression in HME-shp53 cells was associated with a drastic
reduction in p53 binding to both the CDKN1A promoter and
intron 1 of FBL compared with nontreated HME cells (Figures
4D, 4E, S4C, and S4D). These data show that p53 binds the
FBL intron 1 both in the basal condition and when p53 is
activated. Altogether, these results demonstrate that FBL is a
p53 target gene and that FBL expression is directly repressed
by p53.
p53-Mediated Alteration of the rRNA Methylation
Pattern
Because p53 directly represses FBL expression, we determined
whether p53 inactivation alters rRNA methylation by using a
previously described, site-specific semiquantitative RT-qPCR-
based method (Belin et al., 2009; Maden, 1988). We analyzed
the change of rRNA methylation at 18 sites distributed along
the 5.8S, 18S, and 28S rRNAs that are known to be methylated.
These sites include those localizedwithin key functional domains
of rRNAs, i.e., the decoding center (DC) in the 18S rRNA, and the
peptidyl transferase center (PTC) and the helix 69 (H69) of 28S
rRNA. In general, most of the sites were significantly more
frequently methylated in HME-shp53 than in HME cells (Figures
5A and S5A). This overall increase in the site-specific rRNA
methylation pattern is consistent with our finding that FBL
expression level is higher in HME-shp53 than in HME cells, and
suggests that methylation could be regulated in a site-by-site
manner.
Figure 3. p53 Regulates FBL Expression in Human Breast Cell Lines
and Tumors
(A) Quantification of FBL mRNA expression analyzed by RT-qPCR and
normalized to RNA18S.
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CaAs expected, metabolic labeling with [5,6-3H]-uridine and
L-[methyl-3H]-methionine showed that p53 inactivation led to
a significant increase in rRNA synthesis (Figure S5B; Zhai
and Comai, 2000), with a faint increase in the global rRNA
methylation rate (Figure S5C). This showed that the amount
and/or activity of the rRNA methylation machinery was suffi-
cient to sustain the global rRNA methylation rate following
the increase in rRNA synthesis after p53 inactivation. In
addition, because selection of site methylation is ensured by
guide C/D-box snoRNAs that complex with FBL, we verified
whether snoRNA expression levels were altered in p53-inacti-
vated cells. Northern blot analyses revealed a modification of
snoRNA levels according to p53 levels, suggesting that p53
could also be involved in the regulation of some C/D-box
snoRNA as is the case for some H/ACA snoRNP (Figures
S5D–S5F; Krastev et al., 2011). However, no correlation was
found between the amount of snoRNA and the level of the
corresponding rRNA methylation sites (Figures 5A and S5A).
These results show that inactivation of p53 resulted in a site-
specific modification of the rRNA methylation pattern that
correlates with FBL expression.
p53 Alters the Translational Fidelity by Modulating FBL
Expression
The chemical modifications of rRNA that have been conserved
throughout evolution in all species are involved, at least in
eukaryotes, in the control of translational fidelity and in the
control of translation initiation modalities (i.e., CAP-dependent
versus IRES-dependent; Ruggero, 2013; Baxter-Roshek et al.,
2007; Chaudhuri et al., 2007; Ruggero et al., 2003). We first
analyzed two different examples of translational fidelity,
nonsense suppression and amino acid misincorporation (Belin
et al., 2009). The bypass of a premature stop-codon (Figures
5B–5D) and the misincorporation of amino acids (Figures 5E–
5G) were both significantly increased after p53 inhibition or inac-
tivation in different cell lines. This suggested that the translational
alteration could be due to p53-mediated increase of FBL expres-
sion level. To investigate this possibility, we analyzed the misin-
corporation of amino acids in response to knockdown of FBL
expression. As shown in Figure 5G, reduction of FBL expression
in HCT-116-p53/ prevented the increase in amino acids misin-
corporation, demonstrating that the decrease in translational
quality control in response to p53 inhibition is dependent on
FBL overexpression. In contrast, the ability of ribosomes to
induce a 1 frameshift from a severe acute respiratory
syndrome-coronavirus (SARS-CoV)-1 programmed ribosome
frameshift signal was similar in the three cell lines (Figures 5H–
5J). These results suggest that p53 inactivation could decrease
translational fidelity in an FBL-dependent manner.(B) Quantification of FBL protein expression analyzed by western blot. All
graphs represent mean and SD of at least three experiments.
(C) Box-and-whisker plots of FBLmRNA expression quantification in wild-type
p53 (n = 59) versus mutant p53 (n = 21) primary breast tumor samples. The
bottom and the top of the boxes represent the 25th and 75th percentiles,
respectively. The median values are visible as a line, the mean as a cross in the
box and SD as error bars. The p value has been determined by a Mann-
Whitney W test.
See also Figure S3 and Table S1.
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Figure 4. p53 Represses FBL Promoter
Activity by Directly Binding to DNA
(A) Alignment of the two putative p53 response
elements (p53RE-1 and p53RE-2, black arrows)
located within the intron 1 of FBL with the p53RE
consensus (R, G/A; W, A/T; Y, C/T). n, spacer
within p53RE consensus; dotted box, nucleotide
region of the FBL gene cloned in the pFBL-Luc
reporter vector; P1 and P2, primers pairs used in
ChIP assays.
(B and C) Luciferase reporter assays were per-
formed in the absence of p53 () and in the
presence of the wild-type (WT) or the indicated
mutant p53 protein in HCT-116-p53/ (B) and in
HME-shp53 cells (C). Firefly luciferase activity is
normalized to the renilla luciferase activity. Basic,
luciferase reporter vector with no FBL sequence.
(D and E) ChIP using an anti-p53 antibody and
primer pairs P1 (D) or P2 (E) were performed in
nontreated (NT) or 1 nM camptothecin-treated
HME cells, or in HME-shp53 cells. All graphs
represent mean and SD of at least three experi-
ments. *p < 0.05 and ***p < 0.001 according to
Student’s t test.
See also Figure S4.
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by Modulating FBL Expression
To determine whether the CAP- or IRES-dependent mode of
translation was modified, we used a bi-cistronic vector strategy
that has been extensively used to identify a vast number of IRES-
containing sequences (Belin et al., 2009; Komar and Hatzoglou,
2011). At this stage of the study, we focused our analysis on
IGF1R due to its role in tumorigenesis and because IGF1R pos-
sesses the longest GC-rich 50UTR that contains a well-identified
IRES among all human transcripts yet characterized (Giraud
et al., 2001; Pollak et al., 2004). Using a bi-cistronic luciferase
assay, we observed a significant increase in the global luciferase
activity in the p53-inactivated HME-shp53 and HCT-116-p53/
cells compared with cells expressing wild-type p53 (Figure 6A).
This increasewas due to a preference to initiate IRES-dependent
translation. Indeed, the translation of the firefly luciferase driven
by the IRES of IGF1Rwas significantly increased, while no signif-
icant variation was detected for the renilla luciferase driven by a
CAP-dependent mechanism (Figures S6A and S6B). Similar re-
sults were obtained in other HME-derived cell lines (Figures
6B, white bars; Figures S6C and S6D, sc bars). Moreover,
HME and HMLE cells expressed similar levels of firefly luciferase
mRNA and renilla luciferasemRNA independently of variations in
p53 protein levels, which supports the hypothesis of IRES-medi-
ated translational regulation rather than transcriptional regula-
tion of IGF1R expression (Figure S6E).322 Cancer Cell 24, 318–330, September 9, 2013 ª2013 Elsevier Inc.To evaluate whether a similar regula-
tion exists in human cell lines, we
explored the IGF1R IRES activity in
breast cell lines that express wild-type
or mutant p53 protein (Figure 6C). The
activity level of the IGF1R IRES was
significantly higher in themutant p53 cells
that expressed high levels of FBL com-pared with the wild-type p53 cells that expressed low levels of
FBL. Thus, translation initiation mediated by the IGF1R IRES
was higher in breast cell lines that had inactivated p53 instead
of wild-type p53.
To confirm that the IRES activity was modulated by rRNA
methylation, we analyzed the IGF1R IRES activity after using
an FBL-siRNA knockdown approach that reduced the FBL
protein level (Figures S6C, S6D, and S6F). As shown in Fig-
ure 6B, reduction of FBL expression significantly decreases
the IRES-dependent translation initiation of IGF1R in HME,
HME-shp53 and HMLE cells. This result demonstrates that
the efficiency of IRES-dependent translational initiation is
modulated by rRNA methylation through modulation of FBL
expression.
To determine whether the p53-mediated translational control
of the IGF1RmRNA observed with recombinant expression vec-
tors also occurs with endogenous IGF1R mRNA, we compared
the distribution of the IGF1R mRNA within polysomal fractions
of HME and HME-shp53 cells. The polysomal fraction corre-
sponds to mRNA bound to more than one ribosome and there-
fore contains actively translated mRNA. As shown in Figure 6D,
a significant 12-fold polysomal enrichment in IGF1R mRNA was
observed in HME-shp53 compared with HME cells. In addition, a
significant increase in the IGF1R protein level was observed in
p53-inactivated HMLE cells compared to HME cells indepen-
dently of any variation in IGF1R mRNA levels (Figures 6E and
Figure 5. p53 Regulates the rRNA Methylation Pattern and the Translational Fidelity of Ribosomes
(A) The fold difference in rRNAmethylation at 18 sites distributed throughout the 5.8S, 18S, and 28S rRNAs between HME-shp53 andHME cells were analyzed by
RT-qPCR.
(B–J) Translational fidelity was analyzed by transfecting cells with the pGL3mut1 vector (premature stop mutant, B–D), the pGL3mut2 vector (amino acid sub-
stitution mutant, E–G), or the SARS-CoV 1 programmed ribosome frameshift vector (H–J) in the indicated cells. (G) Translational fidelity was analyzed in
nontransfected cells (NT) and after transfection of siRNA control (sc) or siRNA targeting FBL (si-FBL). FBL expression levels were verified bywestern blot (G, lower
panel). All graphs represent mean and SD of at least three experiments. *p < 0.05 and ***p < 0.001 according to Student’s t test.
See also Figure S5.
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the translation of IGF1R mRNA.
To investigate whether this p53-mediated translational control
is restricted to IGF1RmRNA, we analyzed translational control of
several other known cellular and viral mRNAs containing IRESs,
including MYC, FGF1, FGF2, and VEGFA that play key roles in
oncogenesis (Dang, 2012; Turner and Grose, 2010; Carmeliet
and Jain, 2011) and encephalomyocarditis virus. Bi-cistronic
luciferase assays and mRNA polysomal profiling assays showed
an increase of translational efficiency of thesemRNA in p53 inac-
tivated cells compared to p53 wild-type cells (Figures S6G–S6I).
Altogether these results show that p53 inactivation impacts the
translational control of several genes involved in tumorigenesis
through deregulation of FBL expression.
FBL Overexpression Contributes to Tumorigenesis
Six independent stable clones derived from MCF7 cells overex-
pressing either a FBL-GFP protein or a GFP protein were devel-
oped (Figure S7A) to determine the effect of FBL overexpression
on several characteristics of cancer cells. Cell proliferation of the
stable clones was first monitored for 72 hr and the index of cell
proliferation was calculated from the slope of the growth curve
(Figure 7A). Cells overexpressing FBL-GFP exhibit a significant
2-fold increase in proliferation rate compared with GFP control
cells. To determine whether the FBL-induced cell proliferation
is mediated by IGF1R, whose translation is increased in FBL-
overexpressing cells, proliferation of two clones was monitored
in response to Osi-906, an IGF1R tyrosine kinase activity inhibi-
tor (Figure 7B; Mulvihill et al., 2009). Inhibition of IGF1R pathway
activity abolished the difference in proliferation rate between
GFP-G3 and FBL-GFP-F2 clones, suggesting that IGF1R
pathway activity is required in these cells, for FBL-induced cell
proliferation.
Anchorage-independent cell proliferation was then investi-
gated using soft agar assays. Compared to GFP control clones,
those overexpressing FBL-GFP formed significantly more
colonies (Figures 7C and 7D). Finally, the effect of FBL overex-
pression on cell growth in response to doxorubicin treatmentwas
investigated (Figure 7E). A significantly higher concentration of
doxorubicin is required to reach 50% of inhibitory effect in FBL-
GFP cells compared to GFP control cells (mean half-maximal
inhibitory concentration [IC50]: 24.6 mM versus 53.1 mM, respec-
tively). Altogether, these data show that FBL overexpression
promotes cell proliferation in both an anchorage-dependent
and -independent manner and protects the MCF7 breast cancer
cells from doxorubicin. Moreover, the FBL-induced cell prolifer-
ation required IGF1R pathway, supporting the notion that FBL
overexpression can directly contribute to tumorigenesis by
altering translational control of key cancer genes.Figure 6. p53 Regulates the IGF1R IRES-Dependent Translation
(A and B) The IGF1R IRES-dependent translation initiation was determined by us
downregulation of FBL by siRNA approach (B).
(C) Analysis of the IGF1R IRES-dependent translation initiation in a panel of brea
(D) Typical polysomal profiles after fractionation of postmitochondrial supernatan
(upper). The distribution of the IGF1R mRNA within polysomes was determined
(E and F) Endogenous IGF1R expression at mRNA (E, black bars) and protein le
represent mean and SD of at least three experiments. *p < 0.05, **p < 0.01 and *
See also Figure S6.
CaHigh Levels of FBL Are an Independent Marker of a Poor
Outcome in Breast Cancer
To investigate whether the level of FBLmRNA in tumors is asso-
ciated with prognosis, we analyzed the relapse-free survival and
the breast cancer-specific survival of patients with breast cancer
in regard to FBL expression. High expression of FBLmRNA was
significantly associated with a poor relapse-free survival rate and
poor breast cancer-specific survival rate (Figures 7F and 7G).We
also performed retrospective statistical analyses of published
gene expression array data (Gyo¨rffy et al., 2010; Sabatier et al.,
2011; Weigelt et al., 2005). This investigation confirmed that
the high levels of FBL mRNA are associated with poor breast
cancer-specific survival and relapse-free survival rates (Figures
S7B–S7F).
However, because the high levels of FBL expression are asso-
ciated with p53 mutations and because p53 mutations are
known to be associated with poor disease-free and overall sur-
vival rates (Olivier et al., 2006), a multivariate analysis was con-
ducted to adjust for possible confounding variables. The analysis
included the number of invaded lymph nodes, histological grade,
estrogen and progesterone receptors status, ErbB2 status, p53
mutation status, and FBL mRNA levels. The best model associ-
atedwith poor survival contained two independentmarkers: pro-
gesterone receptor-negative status and high FBL expression
(Table S2). These analyses showed that FBL expression is asso-
ciated with poor survival independent of other commonly used
clinical markers.
DISCUSSION
It is now clearly established that ribosome synthesis is increased
in cancers due to the overexpression of oncogenes or the inac-
tivation of tumor suppressor genes leading to a sustained in-
crease in RNA Pol I activity (Bywater et al., 2012). Moreover,
studies performed in different animal and cellular models of
various eukaryotic organisms have shown that heterogeneity in
ribosome composition, due to regulated posttranscriptional
modifications of ribosomal proteins and rRNA, is likely to be
the more common mechanism (Xue and Barna, 2012). Xue and
Barna have made detailed contributions to extend the concept
of ‘‘specialized ribosomes’’ to eukaryotes and highlighted the
adaptive capabilities of the ribosomes in the control of cell fate
through selective protein synthesis. Moreover, it is now well
demonstrated that within the ribosomes, the rRNAs catalyze
and control protein synthesis through their ribozyme activity
that could be finely optimized by their rRNAs methylations and
pseudouridylations (Baxter-Roshek et al., 2007; Belin et al.,
2009). In this study, we show a p53-mediated alteration of ribo-
some biogenesis and translational control of cancer cells thating luciferase bi-cistonic vectors in the indicated cells (A) and in cells after the
st cell lines expressing either wild-type or mutant p53 proteins.
ts from HME and HME-shp53 cells in a 10%–40% sucrose gradient are shown
by RT-qPCR (lower).
vels (E, white bars; and F) was analyzed in HME and HMLE cells. All graphs
**p < 0.001 according to Student’s t test.
ncer Cell 24, 318–330, September 9, 2013 ª2013 Elsevier Inc. 325
(legend on next page)
Cancer Cell
p53 Regulates Translation by Modulating Fibrillarin
326 Cancer Cell 24, 318–330, September 9, 2013 ª2013 Elsevier Inc.
Cancer Cell
p53 Regulates Translation by Modulating Fibrillarincould contribute in gene expression dysregulation and cancer
development (Ruggero, 2013).
We demonstrate a role of p53 in the control of rRNA methyl-
ation patterning by directly regulating FBL expression levels
that leads to the synthesis of modified ‘‘cancer ribosomes.’’
The notion that FBL is a p53-target gene is supported by
genome-wide analyses, such as ChIP-seq assays showing that
p53 binds the FBL gene (ENCODE database, Nikulenkov et al.,
2012) and by transcriptomic analysis showing an inverse expres-
sion of FBL in response to p53 inactivation by siRNA or activation
by doxorubicin in several cell lines (Troester et al., 2006). p53
response elements have also been identified in the first intron
of approximately 25% of p53 target genes, some of them being
associated with gene repression, including genes involved in
ribosome biogenesis such as NOLC1, a snoRNP chaperone
gene (Menendez et al., 2009; Krastev et al., 2011).
We found that the methylation pattern of rRNAs varies
between sites, which is consistent with published data (Baxter-
Roshek et al., 2007; Belin et al., 2009; Basu et al., 2011) and sug-
gests that the rRNA modification pattern is modulated in a
site-by-site manner. Our data showed that p53 inactivation is
sufficient to alter rRNA methylation patterning. In addition to
regulating FBL expression, the role of p53 in optimizing the
rRNA functional quality is reinforced by our observations that
the level of some C/D-box snoRNAs is modulated according to
the p53 status and that p53 is involved in the assembly process
of the other major family of snoRNP (H/ACA box; Krastev et al.,
2011). Deciphering the mechanisms by which p53 inactivation
alters the site-specific rRNA methylation pattern through FBL
induction will require biochemical and structural studies
dedicated to the understanding of formation, dynamics, and
activities of the rRNA methylation complex. However, we can
hypothesize that the improper induction of FBL expression
observed in cancer cells leads to an alteration of the coordination
between pre-rRNA production and the rRNA methylation enzy-
matic machineries.
Today, several pieces of data, including ours, indicate that
modulation of methylation at only some rRNA sites is sufficient
to affect the translational regulation process and that it could
alter cellular behavior without inducing a lethal phenotype
(King et al., 2003; Baudin-Baillieu et al., 2009; Higa-Nakamine
et al., 2012). Indeed, the depletion of methylation of several
rRNA methylation sites in yeast and human cells has been asso-
ciated with a decrease in translation fidelity (such as an increase
in nonsense suppression, frameshifts, and amino acid misincor-
poration; Baxter-Roshek et al., 2007; Baudin-Baillieu et al.,
2009). Moreover, modulating rRNA methylation by RPL13aFigure 7. Contribution of FBL Overexpression to Cancer Phenotype
(A) Cell proliferation of three each independent stable MCF7 clones expressing F
(B) Proliferation of the indicated cell clones not treated (NT) or treated with 1 mM
(C andD) Anchorage-independent growth ofMCF7 clones using soft agar assay. R
in three experiments are shown in (D).
(E) Impact of FBL overexpression on drug response was investigated by determ
p values have been determined by a Mann-Whitney W test.
(F and G) Kaplan-Meier analysis of relapse-free survival rates (event = relapse) (F
cancer disease) (G) according to FBL mRNA level in primary breast tumor samp
expression groups.
See also Figure S7 and Table S2.
Cadepletion in HeLa cells modified the control of the translation
initiation by IRES (Basu et al., 2011). Modification in the rRNA
methylation pattern in breast cancer cells exhibiting an induced
aggressive phenotype was also associated with the alteration of
IRES activity of key factors such as vascular endothelial growth
factor (VEGF) and p53 (Belin et al., 2009). In the present study,
we demonstrate that the repression of FBL expression by p53
is accompanied by an increase of IRES-dependent translation
initiation, affecting cellular as well as a viral IRES-containing
mRNAs. These data are consistent with previous reports
showing that the FGF2 mRNA translation is inhibited by p53,
whereas the FGF2 mRNA IRES is aberrantly activated in
transformed cells when p53 is inactivated (Galy et al., 2001). It
remains to systematically explore the effect of methylation
sites, individually and as a pattern, in the intrinsic activity of
the ribosome.
Modulation of intrinsic activity of the ribosome by altering
rRNA methylation may involve structural changes of ribosomes.
The inhibition of rRNA methylation altered the IRES translation
initiation by impairing the association of the 40S and 60S sub-
units (Basu et al., 2011). Moreover, structural and biochemical
studies showed that ribose methylation modifies the conforma-
tional state of the RNA backbone, stabilizes the RNA loops, and
influences the overall structure of the modified RNA regions.
Ribose methylation helps maintain the tertiary structure of
rRNAs and potentially the rRNA-mRNA, rRNA-tRNA or rRNA-
protein interactions (Blanchard and Puglisi, 2001; Liang et al.,
2009). Consistently, several 18S rRNA regions promote struc-
tural modifications when a viral IRES is bound to the 40S subunit
(Spahn et al., 2004) and the efficient translation of IGF1RmRNA
results from its IRES directly contacting an 18S rRNA domain
through a Shine-Dalgarno-like interaction (Meng et al., 2010).
These data support the notion that rRNA methylation could
participate in translational control by regulating IRES translation
initiation.
Our clinical analysis shows that a high level of FBL in primary
breast tumors is associated with poor survival independent of
other biological markers. Elevated expression levels of FBL
were previously reported in primary and metastatic prostate
cancers compared with normal prostate epithelium and in squa-
mous cell cervical carcinoma compared with normal cervix
samples (Choi et al., 2007; Koh et al., 2011; Su et al., 2013).
Furthermore, we have shown the direct contribution of FBL over-
expression in tumorigenesis. The maintenance and progression
of cancer phenotype induced by FBL-mediated enhanced trans-
lation may involve several key cancer proteins whose synthesis
is dependent upon IRES-containing mRNA. As shown here,BL-GFP (F1, F2, and F3) or GFP (G1, G2, and G3).
Osi-906 for 72 hr.
epresentative images are shown in (C) and the numbers of colonies determined
ining the IC50 of doxorubicin using MTS assays. Error bars represent SD. The
) and of breast cancer-specific survival rates (event = death related to breast
les. The data are dichotomized at the upper quartile value into high and low
ncer Cell 24, 318–330, September 9, 2013 ª2013 Elsevier Inc. 327
Figure 8. Model of the Implication of p53 in
the Control of Ribosomes Quantity and
Ribosomes Quality, and Their Conse-
quences on Translation
In cells expressing functional p53 (top), p53
negatively regulates RNA Pol I activity to control
ribosome quantity and FBL expression levels to
control ribosome quality. This regulation would
aim to coordinate the methylation of ribosomes
and the rate of ribosome production according to
the cell needs. These quality-controlled ribosomes
allow a high translational fidelity together with a
correct control of the balance between CAP- and
IRES-dependent initiation of translation. In cells
expressing a mutant or nonfunctional p53
(bottom), loss of the repression of RNA Pol I
activity leads to an increase in rRNA synthesis.
In parallel, p53 inactivation leads to an increase
in FBL expression levels, resulting in a modifica-
tion of the rRNA methylation patterns. Ribosomes
with modified rRNA methylated translate mRNA
with a lower fidelity (bypass of stop codon, amino
acid misincorporation) and are more likely to
initiate translation through IRES of mRNA coding
for pro-oncogenic, anti-apoptotic, and survival
proteins.
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p53 Regulates Translation by Modulating Fibrillarinthese proteins may include IGF1R, which is involved in tumor
progression, cell survival, and response to chemotherapy (Pollak
et al., 2004), c-Myc, which exhibits pleiotropic pro-oncogenic
functions (Dang, 2012), FGF1/2, which are involved in epithe-
lial-mesenchymal transition (Sakuma et al., 2012), and VEGFA,
which is involved in tumoral angiogenesis (Carmeliet and Jain,
2011). Thus, high levels of FBL observed in human samples
could have a role in tumor progression and could affect the
clinical outcome of patients through alteration of translational
regulation.
Our results allow us to propose a model in which p53 regu-
lates not only the ribosome production rate, but also their
structure, function, and intrinsic activity (Figure 8). In this
model, p53 alteration in pathological cells results in the pro-
duction of ribosomes with decreased translational fidelity and
increased translation of the IRES-containing mRNAs selec-
tively. Thus, the p53-mediated ribosome alterations could be
in part responsible for the ‘‘translational instability’’ of cancer
cells and contribute to the expression of the continuously328 Cancer Cell 24, 318–330, September 9, 2013 ª2013 Elsevier Inc.growing class of translationally regu-
lated cancer-promoting genes (Ruggero,
2013).
Finally, the detailed description of
rRNA chemical modification patterning
in cancer cells, occurring in part through
the p53-mediated regulation of ribosome
biogenesis enzymatic machineries, and
the increasing knowledge of the ribo-
some structure at the atomic level (Anger
et al., 2013), opens up the possibility
to target these ‘‘cancer ribosomes’’ to
develop anticancer molecules using
strategies similar to those used for thedevelopment of antibiotics specifically targeting prokaryotic
ribosomes (Yonath, 2009).
EXPERIMENTAL PROCEDURES
Cell Culture, Transfection, and Luciferase Assay
Cells were maintained in culture following ATCC recommendations. siRNA
and plasmids (Belin et al., 2009) were transfected using lipofectamine 2000
(Invitrogen). Cells were treated with 2 mg/ml doxorubicin or 1 nM camptothecin
(Sigma). Luciferase activity was measured using the Dual Luciferase Reporter
Assay kit (Promega). Anchorage-dependent cell proliferation was analyzed
using a real-time monitoring cell proliferation assay based on variation of
electric impedance using the xCELLigence RTCA system (ACEA Biosciences)
for 72 hr in nontreated cells or in presence of 1 mM Osi-906 (Selleckchen).
Anchorage-independent cell proliferation was analyzed by soft agar assays.
The IC50 values for doxorubicin were determined by MTS assays (Promega).
Western Blot and Chromatin Immunoprecipitation
Protein extraction and western blot were performed as described (Belin
et al., 2010) using the following antibodies: anti-FBL (38F3, Abcam); anti-p53
(DO-1, Santa Cruz); anti-b-actin (AC-15, Sigma); anti-Mdm2 (4B2, Bethyl
Cancer Cell
p53 Regulates Translation by Modulating FibrillarinLaboratories); anti-p21 (F-5, Santa Cruz); and anti-IGF1Ra (N20, Santa Cruz).
For ChIP assays, chromatin was prepared from 1% formaldehyde fixed cells
by sonication. Immunoprecipitation was performed on 200-1000 bp DNA frag-
ments using the DO-1 anti-p53 antibody and immunoprecipitated DNA was
quantified by qPCR using Sybr Green technology.
Total mRNA, Polysomal mRNA, and rRNAMethylation Quantification
Total RNA and RNA issued from cytosolic and polysomal fractions was ex-
tracted and purified using either Trizol reagent (Invitrogen) or TriPure Isolation
reagent (Roche). Cytosolic ribosomes were obtained from postmitochondrial
fractions, and polysomal ribosomes by separation of postmitochondrial frac-
tions on a 10%–40% sucrose gradient by ultracentrifigation. Total, cytosolic,
and polysomal mRNA levels were quantified by RT-qPCR using M-MLV and
Sybr Green technologies as described (Ghayad et al., 2009). Site-specific
rRNA methylation was quantified using a RT-qPCR based method, which re-
lies on the inhibition of reverse transcription reaction by ribose methylation
at low dNTP concentration and on the detection of total rRNA as an internal
reference, by reverse transcription at high dNTP concentration (Belin et al.,
2009). RT products were then quantified by qPCR.
Breast Tumor Samples
FBL mRNA expression was analyzed in a cohort of 80 primary breast tumors
collected at Ninewells Hospital from white women who received no neoadju-
vant treatment prior surgery (Tayside Tissue Bank, Dundee; Table S1).
Informed consent was obtained from all patients and ethical approval was
received from the Tayside Tissue Bank (REC Reference 07/S1402/90) under
delegated authority from the Local Research Ethics Committee. Relapse-
free survival was calculated among breast cancer patients from the date of
diagnosis to the date of relapse (event = relapse). Breast cancer-specific sur-
vival was calculated from the date of diagnosis to the date of breast cancer
specific death (event = death related to breast cancer disease). The character-
ization of the classical molecular markers (histological grade, invaded lymph
node, p53 mutation as well as estrogen, progesterone, and errB2 status)
was previously determined and reported (Bourdon et al., 2011).
Statistical Analyses
Statistical analyses were performed using the Statgraphics 3 plus software
(Statgraphics Centurion). The log-rank test (univariate analysis), Kaplan-Meier
plots, and Cox proportional hazards model (multivariate analysis) were per-
formed using SPSS Software. A p value < 0.05 was considered to be statisti-
cally significant. All graphs present themean and standard variations of at least
three independent experiments and Student’s t test has been performed for
experimental data.
Experimental procedures are detailed in the Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2013.08.013.
ACKNOWLEDGMENTS
This work was supported by Centre Le´on Be´rard, CNRS, INSERM, Universite´
Claude Bernard Lyon 1, Ecole Normale Supe´rieure de Lyon, Cance´ropoˆles
GSO and CLARA, ARC, FRM, ANR (Oncoscreen), and Ligue Contre le Cancer.
It was funded by grants from Re´gion Rhoˆne-Alpes (the´matiques prioritaires
and Cluster 10), Ligue Contre le Cancer (Comite´ du Rhoˆne), Institut National
contre le Cancer (RIBOCAN). V.M. is a recipient of a postdoctoral fellowship
from the Centre Le´on Be´rard. S.B. and G.T. are recipients of doctoral fellow-
ships from the Ligue Contre le Cancer and from ARC for S.B. We thank Carine
Jolyon for her technical assistance.
Received: June 20, 2012
Revised: July 8, 2013
Accepted: August 12, 2013
Published: September 9, 2013CaREFERENCES
Anger, A.M., Armache, J.P., Berninghausen, O., Habeck, M., Subklewe, M.,
Wilson, D.N., and Beckmann, R. (2013). Structures of the human and
Drosophila 80S ribosome. Nature 497, 80–85.
Barna, M., Pusic, A., Zollo, O., Costa, M., Kondrashov, N., Rego, E., Rao, P.H.,
and Ruggero, D. (2008). Suppression of Myc oncogenic activity by ribosomal
protein haploinsufficiency. Nature 456, 971–975.
Bashan, A., and Yonath, A. (2008). Correlating ribosome function with high-
resolution structures. Trends Microbiol. 16, 326–335.
Basu, A., Das, P., Chaudhuri, S., Bevilacqua, E., Andrews, J., Barik, S.,
Hatzoglou, M., Komar, A.A., and Mazumder, B. (2011). Requirement of rRNA
methylation for 80S ribosome assembly on a cohort of cellular internal ribo-
some entry sites. Mol. Cell. Biol. 31, 4482–4499.
Baudin-Baillieu, A., Fabret, C., Liang, X.-H., Piekna-Przybylska, D., Fournier,
M.J., and Rousset, J.-P. (2009). Nucleotide modifications in three functionally
important regions of the Saccharomyces cerevisiae ribosome affect transla-
tion accuracy. Nucleic Acids Res. 37, 7665–7677.
Baxter-Roshek, J.L., Petrov, A.N., and Dinman, J.D. (2007). Optimization of
ribosome structure and function by rRNA base modification. PLoS ONE 2,
e174.
Belin, S., Beghin, A., Solano-Gonza`lez, E., Bezin, L., Brunet-Manquat, S.,
Textoris, J., Prats, A.-C., Mertani, H.C., Dumontet, C., and Diaz, J.-J. (2009).
Dysregulation of ribosome biogenesis and translational capacity is associated
with tumor progression of human breast cancer cells. PLoS ONE 4, e7147.
Belin, S., Kindbeiter, K., Hacot, S., Albaret, M.A., Roca-Martinez, J.X.,
The´rizols, G., Grosso, O., and Diaz, J.-J. (2010). Uncoupling ribosome biogen-
esis regulation from RNA polymerase I activity during herpes simplex virus
type 1 infection. RNA 16, 131–140.
Blanchard, S.C., and Puglisi, J.D. (2001). Solution structure of the A loop of 23S
ribosomal RNA. Proc. Natl. Acad. Sci. USA 98, 3720–3725.
Bourdon, J.-C., Khoury, M.P., Diot, A., Baker, L., Fernandes, K., Aoubala, M.,
Quinlan, P., Purdie, C.A., Jordan, L.B., Prats, A.-C., et al. (2011). p53 mutant
breast cancer patients expressing p53g have as good a prognosis as wild-
type p53 breast cancer patients. Breast Cancer Res. 13, R7.
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J.P.,
Sedivy, J.M., Kinzler, K.W., and Vogelstein, B. (1998). Requirement for p53
and p21 to sustain G2 arrest after DNA damage. Science 282, 1497–1501.
Bywater, M.J., Poortinga, G., Sanij, E., Hein, N., Peck, A., Cullinane, C., Wall,
M., Cluse, L., Drygin, D., Anderes, K., et al. (2012). Inhibition of RNA polymer-
ase I as a therapeutic strategy to promote cancer-specific activation of p53.
Cancer Cell 22, 51–65.
Carmeliet, P., and Jain, R.K. (2011). Molecular mechanisms and clinical appli-
cations of angiogenesis. Nature 473, 298–307.
Cartharius, K., Frech, K., Grote, K., Klocke, B., Haltmeier, M., Klingenhoff, A.,
Frisch, M., Bayerlein, M., and Werner, T. (2005). MatInspector and beyond:
promoter analysis based on transcription factor binding sites. Bioinformatics
21, 2933–2942.
Cech, T.R. (2000). Structural biology. The ribosome is a ribozyme. Science
289, 878–879.
Chaudhuri, S., Vyas, K., Kapasi, P., Komar, A.A., Dinman, J.D., Barik, S., and
Mazumder, B. (2007). Human ribosomal protein L13a is dispensable for
canonical ribosome function but indispensable for efficient rRNA methylation.
RNA 13, 2224–2237.
Choi, Y.W., Kim, Y.W., Bae, S.M., Kwak, S.Y., Chun, H.J., Tong, S.Y., Lee,
H.N., Shin, J.C., Kim, K.T., Kim, Y.J., and Ahn, W.S. (2007). Identification of
differentially expressed genes using annealing control primer-based
GeneFishing in human squamous cell cervical carcinoma. Clin. Oncol.
(R Coll Radiol) 19, 308–318.
Dang, C.V. (2012). MYC on the path to cancer. Cell 149, 22–35.
Demeshkina, N., Jenner, L., Westhof, E., Yusupov, M., and Yusupova, G.
(2012). A new understanding of the decoding principle on the ribosome.
Nature 484, 256–259.ncer Cell 24, 318–330, September 9, 2013 ª2013 Elsevier Inc. 329
Cancer Cell
p53 Regulates Translation by Modulating FibrillarinElenbaas, B., Spirio, L., Koerner, F., Fleming, M.D., Zimonjic, D.B., Donaher,
J.L., Popescu, N.C., Hahn, W.C., and Weinberg, R.A. (2001). Human breast
cancer cells generated by oncogenic transformation of primary mammary
epithelial cells. Genes Dev. 15, 50–65.
Galy, B., Cre´ancier, L., Zanibellato, C., Prats, A.-C., and Prats, H. (2001).
Tumour suppressor p53 inhibits human fibroblast growth factor 2 expression
by a post-transcriptional mechanism. Oncogene 20, 1669–1677.
Ghayad, S.E., Vendrell, J.A., Bieche, I., Spyratos, F., Dumontet, C., Treilleux, I.,
Lidereau, R., and Cohen, P.A. (2009). Identification of TACC1, NOV, and
PTTG1 as new candidate genes associated with endocrine therapy resistance
in breast cancer. J. Mol. Endocrinol. 42, 87–103.
Giraud, S., Greco, A., Brink, M., Diaz, J.-J., and Delafontaine, P. (2001).
Translation initiation of the insulin-like growth factor I receptor mRNA is medi-
ated by an internal ribosome entry site. J. Biol. Chem. 276, 5668–5675.
Gyo¨rffy, B., Lanczky, A., Eklund, A.C., Denkert, C., Budczies, J., Li, Q., and
Szallasi, Z. (2010). An online survival analysis tool to rapidly assess the effect
of 22,277 genes on breast cancer prognosis using microarray data of 1,809
patients. Breast Cancer Res. Treat. 123, 725–731.
Henras, A.K., Soudet, J., Ge´rus, M., Lebaron, S., Caizergues-Ferrer, M.,
Mougin, A., and Henry, Y. (2008). The post-transcriptional steps of eukaryotic
ribosome biogenesis. Cell. Mol. Life Sci. 65, 2334–2359.
Higa-Nakamine, S., Suzuki, T., Uechi, T., Chakraborty, A., Nakajima, Y.,
Nakamura, M., Hirano, N., Suzuki, T., and Kenmochi, N. (2012). Loss of ribo-
somal RNA modification causes developmental defects in zebrafish. Nucleic
Acids Res. 40, 391–398.
King, T.H., Liu, B., McCully, R.R., and Fournier, M.J. (2003). Ribosome struc-
ture and activity are altered in cells lacking snoRNPs that form pseudouridines
in the peptidyl transferase center. Mol. Cell 11, 425–435.
Koh, C.M., Gurel, B., Sutcliffe, S., Aryee, M.J., Schultz, D., Iwata, T., Uemura,
M., Zeller, K.I., Anele, U., Zheng, Q., et al. (2011). Alterations in nucleolar struc-
ture and gene expression programs in prostatic neoplasia are driven by the
MYC oncogene. Am. J. Pathol. 178, 1824–1834.
Komar, A.A., and Hatzoglou, M. (2011). Cellular IRES-mediated translation: the
war of ITAFs in pathophysiological states. Cell Cycle 10, 229–240.
Krastev, D.B., Slabicki, M., Paszkowski-Rogacz, M., Hubner, N.C., Junqueira,
M., Shevchenko, A., Mann, M., Neugebauer, K.M., and Buchholz, F. (2011). A
systematic RNAi synthetic interaction screen reveals a link between p53 and
snoRNP assembly. Nat. Cell Biol. 13, 809–818.
Liang, X.H., Liu, Q., and Fournier, M.J. (2009). Loss of rRNA modifications in
the decoding center of the ribosome impairs translation and strongly delays
pre-rRNA processing. RNA 15, 1716–1728.
Maden, B.E. (1988). Locations ofmethyl groups in 28 S rRNA of Xenopus laevis
and man. Clustering in the conserved core of molecule. J. Mol. Biol. 201,
289–314.
Menendez, D., Inga, A., and Resnick, M.A. (2009). The expanding universe of
p53 targets. Nat. Rev. Cancer 9, 724–737.
Meng, Z., Jackson, N.L., Shcherbakov, O.D., Choi, H., and Blume, S.W. (2010).
The human IGF1R IRES likely operates through a Shine-Dalgarno-like interac-
tion with the G961 loop (E-site) of the 18S rRNA and is kinetically modulated by
a naturally polymorphic polyU loop. J. Cell. Biochem. 110, 531–544.
Miller, L.D., Smeds, J., George, J., Vega, V.B., Vergara, L., Ploner, A., Pawitan,
Y., Hall, P., Klaar, S., Liu, E.T., andBergh, J. (2005). An expression signature for
p53 status in human breast cancer predicts mutation status, transcriptional
effects, and patient survival. Proc. Natl. Acad. Sci. USA 102, 13550–13555.
Montanaro, L., Calienni, M., Ceccarelli, C., Santini, D., Taffurelli, M., Pileri, S.,
Trere´, D., and Derenzini, M. (2008). Relationship between dyskerin expression
and telomerase activity in human breast cancer. Cell. Oncol. 30, 483–490.
Mulvihill, M.J., Cooke, A., Rosenfeld-Franklin, M., Buck, E., Foreman, K.,
Landfair, D., O’Connor, M., Pirritt, C., Sun, Y., Yao, Y., et al. (2009).
Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the
IGF-1 receptor and insulin receptor. Future Med Chem 1, 1153–1171.
Newton, K., Petfalski, E., Tollervey, D., and Ca´ceres, J.F. (2003). Fibrillarin is
essential for early development and required for accumulation of an intron-
encoded small nucleolar RNA in the mouse. Mol. Cell. Biol. 23, 8519–8527.330 Cancer Cell 24, 318–330, September 9, 2013 ª2013 Elsevier IncNikulenkov, F., Spinnler, C., Li, H., Tonelli, C., Shi, Y., Turunen, M., Kivioja, T.,
Ignatiev, I., Kel, A., Taipale, J., and Selivanova, G. (2012). Insights into p53
transcriptional function via genome-wide chromatin occupancy and gene
expression analysis. Cell Death Differ. 19, 1992–2002.
Olivier, M., Langerød, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., Theillet,
C., Rodriguez, C., Lidereau, R., Bie`che, I., et al. (2006). The clinical value of
somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin.
Cancer Res. 12, 1157–1167.
Pollak, M.N., Schernhammer, E.S., and Hankinson, S.E. (2004). Insulin-like
growth factors and neoplasia. Nat. Rev. Cancer 4, 505–518.
Puglisi, J.D. (2009). Resolving the elegant architecture of the ribosome. Mol.
Cell 36, 720–723.
Ruggero, D. (2013). Translational control in cancer etiology. Cold Spring Harb.
Perspect. Biol. 5, a012336–a012336.
Ruggero, D., Grisendi, S., Piazza, F., Rego, E., Mari, F., Rao, P.H., Cordon-
Cardo, C., and Pandolfi, P.P. (2003). Dyskeratosis congenita and cancer in
mice deficient in ribosomal RNA modification. Science 299, 259–262.
Sabatier, R., Finetti, P., Cervera, N., Lambaudie, E., Esterni, B., Mamessier, E.,
Tallet, A., Chabannon, C., Extra, J.M., Jacquemier, J., et al. (2011). A gene
expression signature identifies two prognostic subgroups of basal breast
cancer. Breast Cancer Res. Treat. 126, 407–420.
Sakuma, K., Aoki, M., and Kannagi, R. (2012). Transcription factors c-Myc and
CDX2 mediate E-selectin ligand expression in colon cancer cells undergoing
EGF/bFGF-induced epithelial-mesenchymal transition. Proc. Natl. Acad. Sci.
USA 109, 7776–7781.
Sbisa`, E., Catalano, D., Grillo, G., Licciulli, F., Turi, A., Liuni, S., Pesole, G., De
Grassi, A., Caratozzolo, M.F., D’Erchia, A.M., et al. (2007). p53FamTaG: a
database resource of human p53, p63 and p73 direct target genes combining
in silico prediction and microarray data. BMC Bioinformatics 8(Suppl 1 ), S20.
Spahn, C.M., Jan, E., Mulder, A., Grassucci, R.A., Sarnow, P., and Frank, J.
(2004). Cryo-EM visualization of a viral internal ribosome entry site bound to
human ribosomes: the IRES functions as an RNA-based translation factor.
Cell 118, 465–475.
Su, H., Xu, T., Ganapathy, S., Shadfan, M., Long, M., Huang, T.H., Thompson,
I., and Yuan, Z.M. (2013). Elevated snoRNA biogenesis is essential in breast
cancer. Oncogene. Published online April 1, 2013. http://dx.doi.org/10.1038/
onc.2013.89.
Tollervey, D., Lehtonen, H., Jansen, R., Kern, H., and Hurt, E.C. (1993).
Temperature-sensitive mutations demonstrate roles for yeast fibrillarin in
pre-rRNA processing, pre-rRNA methylation, and ribosome assembly. Cell
72, 443–457.
Troester, M.A., Herschkowitz, J.I., Oh, D.S., He, X., Hoadley, K.A., Barbier,
C.S., and Perou, C.M. (2006). Gene expression patterns associated with p53
status in breast cancer. BMC Cancer 6, 276.
Turner, N., and Grose, R. (2010). Fibroblast growth factor signalling: from
development to cancer. Nat. Rev. Cancer 10, 116–129.
Weigelt, B., Hu, Z., He, X., Livasy, C., Carey, L.A., Ewend, M.G., Glas, A.M.,
Perou, C.M., and Van’t Veer, L.J. (2005). Molecular portraits and 70-gene
prognosis signature are preserved throughout the metastatic process of
breast cancer. Cancer Res. 65, 9155–9158.
Xue, S., and Barna, M. (2012). Specialized ribosomes: a new frontier in gene
regulation and organismal biology. Nat. Rev. Mol. Cell Biol. 13, 355–369.
Yonath, A. (2009). Large facilities and the evolving ribosome, the cellular
machine for genetic-code translation. J. R. Soc. Interface 6(Suppl 5 ), S575–
S585.
Yoon, A., Peng, G., Brandenburger, Y., Zollo, O., Xu, W., Rego, E., and
Ruggero, D. (2006). Impaired control of IRES-mediated translation in X-linked
dyskeratosis congenita. Science 312, 902–906.
Zhai, W., and Comai, L. (2000). Repression of RNA polymerase I transcription
by the tumor suppressor p53. Mol. Cell. Biol. 20, 5930–5938..
